目录
- Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version)
- Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version)
- Chinese guidelines for diagnosis and treatment of pancreatic cancer 2018 (English version)
- Chinese guidelines for diagnosis and treatment of cervical cancer 2018 (English version)
- Secular trends in incidence of lung cancer by histological type in Beijing, China, 2000-2016
- Risk prediction models for lung cancer: Perspectives and dissemination
- Radiomic features from computed tomography to differentiate invasive pulmonary adenocarcinomas from non-invasive pulmonary adenocarcinomas appearing as part-solid groundglass nodules
- Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study
- Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
- Efficacy of endoscopic treatment on patients with severe dysplasia/carcinoma in situ of esophageal squamous cell carcinoma: A prospective cohort study
- Histogram analysis of apparent diffusion coefficient predicts response to radiofrequency ablation in hepatocellular carcinoma
- Alisol B 23-acetate-induced HepG2 hepatoma cell death through mTOR signaling-initiated G1 cell cycle arrest and apoptosis: A quantitative proteomic study
- Nomograms based on HPV load for predicting survival in cervical squamous cell carcinoma: An observational study with a longterm follow-up
- Synthesis and evaluation of 64Cu-radiolabeled NOTA-cetuximab(64Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
- Extensive exploration of T cell heterogeneity in cancers by single cell sequencing